Pharmaceutical Science Advances最新文献

{"title":"Pharmaceutical development of tablets based on cryolyophilized porcine skin","authors":"Oksana Panysheva","doi":"10.1016/j.pscia.2025.100082","DOIUrl":"10.1016/j.pscia.2025.100082","url":null,"abstract":"<div><div>Among natural sources of animal origin, the most similar to human in composition is porcine skin. Crushed cryolyophilized xenoderm of porcine skin from 1st layer is used for preparation a dietary supplement Xenoderm in the form of powder, capsules and tablets. Also, an additional natural active pharmaceutical ingredient is 2nd layer from cryolyophilized xenoderm of porcine skin, which was not used before. In this study, composition and technology of combined tablets based on the powders of the 1st and 2nd layers from the cryolyophilized xenoderm of porcine skin were develop and characterized. It was evaluated pharmaco-technological properties of the tableting blend such as bulk density, tapped density, flowability and angle of repose. The tablets were prepared by direct compression method. They were studied for appearance, uniformity of dosage units, hardness, friability and disintegration. The effect of fillers, disintegrants, and glidants on 9 pharmaco-technological properties of the tableting blend and tablets was investigated using dispersion analysis. By desirability function the advantages of Neusilin® US2, calcium dihydrogen phosphate anhydrous and sorbitol, croscarmellose sodium and polyplasdone XL-10 are shown. The quantities of excipients were investigated using method of random balance. The interaction between quantities of excipients and the quality of tableting blend and tablets was proved using method of regression analysis. Optimal combination of croscarmellose sodium, Neusilin® US2, microcrystalline cellulose 102 and magnesium stearate is justified. New combined tablets under the conventional name Combiderm are obtained by direct compression method. Optimal tablet pressing parameters are selected in the range from 290 ​MPa to 435 ​MPa. We successfully prepared the tablets with a good consumer appearance and conformity pharmacopoeial requirements. The proposed methodology could be an algorithm for the pharmaceutical development of other combined tablets using statistical methods.</div></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"3 ","pages":"Article 100082"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145019030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An investigation into the underlying mechanisms of risperidone-induced antinociception through the cholinergic pathway","authors":"Lawrence Adedayo ,&nbsp;Victor Adesoye ,&nbsp;Olubayode Bamidele ,&nbsp;Idris Azeez ,&nbsp;Oyetola Oyebanjo ,&nbsp;Adeshina Adekeye ,&nbsp;Saminu Samaila ,&nbsp;Nimedia Aitokhuehi ,&nbsp;Olusegun Adebayo ,&nbsp;Gideon Ojo","doi":"10.1016/j.pscia.2025.100086","DOIUrl":"10.1016/j.pscia.2025.100086","url":null,"abstract":"<div><div>Pain is a complex phenomenon involving the perception of physical discomfort caused by tissue damage in the body. Risperidone, a neuroleptic with dopamine (D2) and serotonin (5-HT2) receptor antagonistic potentials, also exhibits antinociceptive properties, however, its use in the treatment of peripheral nociception has received little attention. Hence, this study evaluated the antinociceptive effects of risperidone and its possible mechanism of action. Ninety Swiss mice (23–30 ​g) were divided into two phases: antinociceptive and mechanistic. Antinociceptive activity was assessed using acetic acid-induced writhing and formalin-induced paw-licking tests. In each model, mice were grouped (n ​= ​6) and treated with distilled water (control), risperidone (0.5, 1.0, and 1.5 ​mg/kg), or indomethacin (10 ​mg/kg). Mechanistic studies involved atropine, propranolol, or naloxone co-administered with risperidone (1.5 ​mg/kg). The results of the studies showed that risperidone significantly decreased neurogenic and inflammatory pain in the paw licking test while risperidone 1.5 ​mg/kg significantly decreased writhing in the acetic acid-induced writhing test. In the mechanistic studies, atropine co-administered with risperidone group showed significantly reversed anti-nociception when compared with risperidone 1.5 ​mg/kg alone in the paw-licking test model. Histological assessment of the mice paw tissues using Hematoxylin &amp; Eosin, and Giemsa staining techniques revealed improved infiltration of inflammatory cells, which was significantly decreased in mice pre-treated with atropine, further supporting the analgesic potential of risperidone in the study. This study highlights risperidone's antinociceptive potential and suggests its mechanism is mediated via cholinergic pathways, offering insights into its therapeutic applications that can be implore in pain management.</div></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"3 ","pages":"Article 100086"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144829464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Homologous tumor cell exosome-based drug delivery system co-delivering temozolomide and resveratrol for orthotopic glioblastoma therapy","authors":"Xuemei Wang ,&nbsp;Tao Zhang ,&nbsp;Dandan Zhang ,&nbsp;Yuxin Cao ,&nbsp;Xinxin Wang ,&nbsp;Xiaowei Liu ,&nbsp;Weili Yang ,&nbsp;Yingchao Liu ,&nbsp;Daquan Chen","doi":"10.1016/j.pscia.2025.100075","DOIUrl":"10.1016/j.pscia.2025.100075","url":null,"abstract":"<div><div>Temozolomide (TMZ) is the first-line chemotherapeutic agent for treating glioblastoma multiforme (GBM), but its potency is hampered by inevitable drug resistance and systematic toxicity. Novel strategies that can decrease drug-associated adverse events are urgently needed. Encouraged by the significant pro-apoptotic, anti-inflammatory, and anti-proliferative properties of resveratrol (RES), one of the most widely studied polyphenolic compounds in cancer therapy, we propose a synergistic therapeutic strategy by using the combination of TMZ and RES to inhibit GBM progression. Recently, exosomes (Exos) have received increasing attention as promising drug delivery alternatives with favorable intrinsic features. In this work, Exos derived from homologous U87 ​cells are developed to co-deliver TMZ/RES for GBM therapy, defined as U87-Exos@TMZ/RES. It is found that U87-Exos@TMZ/RES share various advantages, including intrinsic tumor-targeting accumulation with homologous effects, as well as enhanced antitumor activity with synergistic effects of TMZ and RES. Furthermore, the excellent therapeutic effect of U87-Exos@TMZ/RES is also achieved in orthotopic GBM models. Based on these results, this novel U87-Exos@TMZ/RES delivery platform can provide a promising systemic chemotherapy strategy for enhancing GBM treatment.</div></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"3 ","pages":"Article 100075"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144470075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single-walled carbon nanotubes sensors: Preparation and bio-application advances","authors":"Xiaotong Chen ,&nbsp;Difan Wang ,&nbsp;Wenshuo Ding ,&nbsp;Hengchang Zang,&nbsp;Lian Li","doi":"10.1016/j.pscia.2025.100064","DOIUrl":"10.1016/j.pscia.2025.100064","url":null,"abstract":"<div><div>Molecular recognition and detection are the main concerns in the field of biological analysis because they can be affected by various factors. Single-walled carbon nanotube (SWCNTs)-based optical biosensors have been applied in this field owing to their high sensitivity, good fluorescence stability, and tissue transparency. Purification of single-chiral SWCNTs and surface functionalization of SWCNTs are effective strategies for achieving real-time monitoring and high-throughput screening of biological analytes. Combining these technologies with microfluidic platforms and machine learning algorithms further broadens the application areas of sensors and enhances their analytical performance and usefulness in complex biological systems. Therefore, this review first discusses the preparation methods for single-chiral SWCNTs in recent years and introduces covalent and non-covalent functionalization techniques for SWCNTs, including oligonucleotide chains, peptides, and surfactant modifications. Subsequently, we systematically evaluate the applications of functionalized SWCNT biosensors for recognizing small molecules, including gas phase composition, neurotransmitters, and reactive oxygen species. These biosensors have been shown to have high sensitivity and specificity in the detection of a wide range of small molecules, offering a wide range of possibilities for analyzing volatile organic compounds, signaling molecules, and reactive oxygen species within biological systems, and providing new ways of gaining insights into the complex mechanisms of disease progression. Finally, we have analyzed the ability of SWCNT biosensors to recognize biomolecules in various categories, including proteins, nucleic acids, and lipids. Using these sensors for clinical disease diagnosis improves the accuracy and timeliness of diagnosis and opens up new ways to improve patients' prognosis and quality of life. We believe that SWCNT biosensors have great potential for future development in biomedicine.</div></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"3 ","pages":"Article 100064"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143487203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discovery of a long-acting nanocrystal formulation of INND-2201, a new co-drug of pregabalin and palmitoylethanolamide with synergistic analgesic effects","authors":"Xiao-Min Han ,&nbsp;Yang Xiao ,&nbsp;Chao-Nan Huang,&nbsp;Ming-Yue Yin,&nbsp;Ben Xu,&nbsp;Yang-Yang Song,&nbsp;Tao Zhuang,&nbsp;Gui-Sen Zhang","doi":"10.1016/j.pscia.2025.100099","DOIUrl":"10.1016/j.pscia.2025.100099","url":null,"abstract":"<div><div>Chronic pain is a global health problem affecting approximately 30% of the adult population worldwide. Currently available painkillers often showed limited efficacy or serious adverse effects and require frequent administration to maintain therapeutic effects. To develop new long-acting analgesics with synergistic antinociceptive effects, a new co-drug INND-2201 of pregabalin and palmitoylethanolamide (PEA) was synthesized, characterized and prepared as a nanocrystal formulation. INND-2201 was slowly metabolized into pregabalin and PEA in microsomal stability test, and oral INND-2201 exhibited significant and synergistic antinociceptive effects for inflammatory and neuropathic pain with ED₅₀ values of 4.43 and 5.54 ​mg/kg, respectively. Nanocrystals (NCs) of INND-2201 were then prepared by the ball milling method with the particle size of 107.1 ​± ​2.7 ​nm. Intramuscular administration of INND-2201 ​NCs demonstrated prolonged pain relief lasting up to 5 days for chronic inflammatory pain in mice. Acute toxicity test, muscular irritation evaluation, rotarod test and open field test indicated that INND-2201 had a good safety profile. Taken together, INND-2201 ​NCs exerted long-acting analgesic effects and provided a promising strategy for the management of chronic pain.</div></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"3 ","pages":"Article 100099"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145527900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Curative antimalarial efficacy and hepato-renal protective effects of Melochia umbellata leaf extract in rats infected with Plasmodium berghei","authors":"Vincent Ngouana ,&nbsp;Patrick Valere Tsouh Fokou ,&nbsp;Marius Jaures Tsakem Nangap ,&nbsp;Raoul Kemzeu ,&nbsp;Aubin Kamche Youbi ,&nbsp;Fabrice Fekam Boyom","doi":"10.1016/j.pscia.2025.100092","DOIUrl":"10.1016/j.pscia.2025.100092","url":null,"abstract":"<div><div>Malaria remains a major global health issue, particularly in endemic regions. Traditional medicine offers promising remedies, such as <em>Melochia umbellata</em>, a plant used in Cameroonian folk medicine for malaria treatment. While its <em>in vitro</em> antiplasmodial activity has been reported, the safety and curative efficacy of <em>M. umbellata</em> aqueous leaf extract (MULAE) <em>in vivo</em> required further investigation. This study evaluated the curative antimalarial and hepato-renal protective effects of MULAE in a <em>Plasmodium berghei</em>-infected rat model, alongside its phytochemical characterization. Qualitative and quantitative analyses confirmed the presence of pharmacologically active secondary metabolites, including alkaloids, phenols, flavonoids, and saponins. In acute toxicity tests (OECD guideline 423), female rats received single oral doses of MULAE (2000, 5000 ​mg/kg). No mortality or signs of toxicity were observed throughout the 14-day monitoring period, indicating an LD₅₀ greater than 5000 ​mg/kg. For the curative assay, <em>P. berghei</em>-infected rats were treated for five days with MULAE (100, 200, 400 ​mg/kg), chloroquine (10 ​mg/kg), or distilled water. MULAE significantly suppressed parasitemia dose-dependently; the 400 ​mg/kg dose achieved 86.20% chemosuppression. The extract also improved hematological markers (restoring hemoglobin levels to 14.9 ​g/dL at 400 ​mg/kg), mitigated infection-induced weight loss, and reduced organ damage. This organ protection was evidenced by improved blood serum markers (creatinine, ALAT, ASAT, bilirubin, total protein), restored oxidative status, and ameliorated histopathological changes in the liver, kidneys, and spleen. These findings validate the traditional use of <em>M. umbellata</em> and support its potential as a source for novel antimalarial and organ-protective agents.</div></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"3 ","pages":"Article 100092"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145104587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive multi-omics analysis of CD36 in pan-cancers: Evaluating role in prognosis, immune microenvironment, and therapeutic response","authors":"Muhammad Sameer Ashaq ,&nbsp;Shengsong Wang ,&nbsp;Meiqi Guo ,&nbsp;Lingling Wang ,&nbsp;Zhuoran Li ,&nbsp;Yi Wang ,&nbsp;Yufeng Huang ,&nbsp;Yuan Li ,&nbsp;Baobing Zhao","doi":"10.1016/j.pscia.2025.100097","DOIUrl":"10.1016/j.pscia.2025.100097","url":null,"abstract":"<div><div>Cluster of differentiation-36 (CD36) is involved in cellular adhesion, lipid metabolism, immunity, and inflammation. Multiple studies have enlightened the regulatory roles of CD36 in metabolic reprogramming, metastasis, chemoresistance, stemness, immune modulation, senescence, inflammation, and angiogenesis. However, its role in tumorigenesis is still unclear and context-dependent. We performed a comprehensive pan-cancer analysis of CD36 by using data from TCGA, integrating transcriptomic, proteomic, methylation, mutational, immune infiltration, immunotherapy, and drug sensitivity datasets. Expression patterns, clinical associations, prognostic potential, immune interactions, and therapeutic implications were systematically evaluated. We also evaluated CD36-related molecular pathways and immune signatures in cancer by a comprehensive GSEA analysis. We found that CD36 expression pattern is dysregulated in multiple cancer types, whereas higher expression correlated with poor prognosis in LGG, BRCA, CESC, and LAML. <em>CD3</em>6 mRNA showed inverse correlations with methylation levels. GSEA analysis revealed cancer-type-dependent association of CD36 with hallmark pathways, whereas multiple cancer types showed positive correlation with immune and inflammation-related pathways and negative correlation with cell cycle-related pathways. CD36 expression correlated with macrophage infiltration, immune regulators, and immunotherapy outcomes, including T-cell dysfunction and Immune checkpoint blockade (ICB) response. Moreover, drug sensitivity analyses revealed significant associations between CD36 and anticancer compound responses. This study provides a comprehensive and context-dependent landscape of CD36, establishing its oncogenic and immune-regulatory roles. Our findings highlight the potential of CD36 in prognosis, tumor microenvironment, and therapeutic sensitivity, while experimental validation is required to prove therapeutic relevance in cancer therapy and immunotherapy.</div></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"3 ","pages":"Article 100097"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145319554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent progress on formulations of hirudin","authors":"Zheng Bao ,&nbsp;Xingyu Qi ,&nbsp;Suling Zhu ,&nbsp;Mao Zhang ,&nbsp;Xinyue Liu ,&nbsp;Peidong Chen ,&nbsp;Li Zhang ,&nbsp;Ting Geng ,&nbsp;Fang-Fang Cheng","doi":"10.1016/j.pscia.2025.100078","DOIUrl":"10.1016/j.pscia.2025.100078","url":null,"abstract":"<div><div>Hirudin is an effective active ingredient derived from the salivary glands of leech. It is a small peptide molecule consisting of 65–66 amino acids and demonstrates a strong inhibitory effect on thrombin, providing beneficial anticoagulant and antithrombotic properties. However, as a biopharmaceutical peptide, it has some drawbacks such as easy degradation, short half-life, low bioavailability, and high risk of hemorrhage in clinical use. To overcome these challenges, various formulations were developed. In this work, a comprehensive review of research progress was provided in both traditional and novel hirudin formulations, spanning from lyophilized powders to biotechnology-based pharmaceuticals, covering various dosage forms to offer comprehensive references for field research. Firstly the advantages and limitations of conventional preparations were assessed such as freeze-dried powders, capsules, and injections. Then a detailed exploration of frontier strategies including nanotechnology-based delivery systems, transdermal formulations, and biotechnology-driven prodrug designs were conducted. This article aims to comprehensively analyze cutting-edge advancements in hirudin preparation research, providing updated information for relevant researchers by integrating traditional dosage optimization with breakthrough emerging technologies.</div></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"3 ","pages":"Article 100078"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144482432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"GLDC interacts with VPS34 to inhibit tumorigenesis and epithelial-mesenchymal transition in hepatocellular carcinoma\" [Adv. Pharmaceut. Sci. (3), (2025), 100072].","authors":"Zan Song, Hao Dong, Kailing Zhang, Bingke Qiao, Leilei Li, Zhicheng Zhang, Zhili Fan, Jing Li, Yu Li, Mengfei Liu, Ying Liu, Xinyu Gu, Tao Zhang","doi":"10.1016/j.pscia.2025.100081","DOIUrl":"10.1016/j.pscia.2025.100081","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1016/j.pscia.2025.100072.].</p>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"3 ","pages":"100081"},"PeriodicalIF":0.0,"publicationDate":"2025-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12710011/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146000352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A biodegradable antimicrobial oligomer-containing hydrogel for drug-resistant bacteria-infected skin wound treatment","authors":"Min Wang ,&nbsp;Xinyun Zeng ,&nbsp;Xiuping Wang ,&nbsp;Zhiyuan Zhang ,&nbsp;Siwei Guo ,&nbsp;Yang Deng ,&nbsp;Xin Li ,&nbsp;Lin Yao ,&nbsp;Jiaqi Li ,&nbsp;Wing-Leung Wong ,&nbsp;Yugang Bai ,&nbsp;Xinxin Feng","doi":"10.1016/j.pscia.2025.100091","DOIUrl":"10.1016/j.pscia.2025.100091","url":null,"abstract":"<div><div>Antibiotic resistance poses a serious global threat, contributing to severe clinical outcomes such as skin and soft tissue infections. Effective treatment of these infections requires both potent antimicrobial activity against resistant pathogens and wound dressings that can conform closely to the wound site. Degradable antimicrobial polymers offer a promising solution to this challenge. Unlike traditional antibiotic-loaded dressings, which often fail against multidrug-resistant (MDR) bacteria, antimicrobial polymers can effectively overcome resistance barriers. Moreover, these polymers can be easily incorporated into wound dressing materials—hydrogels being a particularly advantageous platform due to their biocompatibility and wound-conforming properties. In this study, we developed a modular strategy to integrate a biodegradable cationic antimicrobial oligomer, oligoamidine (<strong>OA1</strong>), into a thermo-responsive hydrogel. <strong>OA1</strong> exerts a triple antibacterial mechanism involving membrane disruption, DNA binding, and ROS generation. The resulting hydrogel system can be conveniently formulated by simple mixing and undergoes a solution-gel transition at body temperature, enabling easy application to infected skin wounds. Importantly, the hydrogel matrix does not impair the bactericidal efficacy of <strong>OA1</strong>, preserving its full antimicrobial potential. This synergistic system offers an effective and user-friendly approach for treating wounds infected with MDR pathogens.</div></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"3 ","pages":"Article 100091"},"PeriodicalIF":0.0,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145004022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}